4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Kintor Pharmaceutical Limited (9939) operates in the Biotechnology industry and is headquartered in Suzhou, China with about 123 employees. Its market capitalization is roughly CNY 849 million. In the fiscal year ended 2025-12-31, 9939 reported CNY 33M in revenue and (CNY 200M) in net income.
Kintor Pharmaceutical Limited, a clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CNY 33M | CNY 5M | CNY 0M | CNY 0M | — |
| Gross Profit | CNY 8M | (CNY 5M) | (CNY 42M) | CNY 0M | — |
| Operating Income (EBIT) | (CNY 173M) | (CNY 153M) | (CNY 1.1B) | (CNY 969M) | — |
| Net Income | (CNY 200M) | (CNY 155M) | (CNY 1.1B) | (CNY 954M) | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 341M | CNY 515M | CNY 869M | CNY 2.1B | — |
| Total Liabilities | CNY 158M | CNY 221M | CNY 411M | CNY 560M | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 9939 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms